Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,301.93 +55.25 (+1.05%) Dow
39,844.58 +286.47 (+0.72%) Nasdaq
16,733.02 +221.84 (+1.34%) Bitcoin USD
65,530.80 +4,124.18 (+6.72%) CMC Crypto 200
1,380.99 +113.05 (+8.93%)
SLS May 2024 3.000 put
| Previous close | 1.6000 |
| Open | N/A |
| Bid | 1.1500 |
| Ask | 2.1500 |
| Strike | 3.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.6000 - 1.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
GlobeNewswireSELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - - Announced Positive Phase 2 Data of SLS009 Demonstrating 100% Response Rate in r/r AML Patients with ASXL1 Mutation at 30 mg BIW Dose and 62% Anti-Leukemic Activity Across All Dose Levels; Additional Data Expected in the Secon
- GlobeNewswire
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, All Patients Alive: Further Support for Potential Accelerated Approval Pathway in Defined Patient Population – - SLS009 Exhibits Strong Anti-Leukemic Activity in 62% of Patients with a Favorable Safety Profile Across All Dose
- GlobeNewswire
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications – – IDMC Will Convene Again Ahead of Scheduled IDMC Charter Meeting – – Next Efficacy and Safety Assessment of All REGAL Patients (n=127) in June 2024 – NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical
